# Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

> **NCT03852719** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 150 (actual)

## Conditions studied

- Chronic Hepatitis Delta

## Interventions

- **DRUG:** Bulevirtide

## Key facts

- **NCT ID:** NCT03852719
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2020-11-26
- **Final completion:** 2024-08-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852719, "Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03852719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*